Key result
Concomitant TAP during endoscopic mitral surgery is linked to lower sPAP with similar 30-day mortality.
Why the study?
The impact of concomitant tricuspid annuloplasty on clinical outcomes during totally endoscopic mitral valve surgery was unclear.
Does concomitant tricuspid annuloplasty affect clinical outcomes in patients undergoing totally endoscopic mitral valve surgery?
Cohort (n=143)
No
Does concomitant tricuspid annuloplasty affect clinical outcomes in patients undergoing totally endoscopic mitral valve surgery?
Concomitant tricuspid annuloplasty during totally endoscopic mitral valve surgery is safe and improves postoperative systolic pulmonary artery pressure without increasing mortality or serious adverse events, despite longer operative times.
Concomitant TAP appears safe in endoscopic mitral surgery; leaves open need for randomized trials on long-term benefit.
Background: This study aimed to determine how concomitant tricuspid annuloplasty (TAP) affects the clinical outcomes of patients undergoing totally endoscopic mitral valve surgery.Methods: This was a single-centre, retrospective study. Between January 2019 and June 2020, 143 patients who underwent totally endoscopic mitral valve surgery in our institution were enrolled. Ninety-two patients who underwent isolated mitral valve surgery were categorized into the minimally invasive mitral valve surgery (MIMVS) group (n=92), and patients who underwent mitral valve surgery with concomitant TAP were categorized into the MIMVS-TAP (n=51) group. Clinical data were collected from all patients, including demographic and perioperative data. We conducted propensity score matching (PSM) by using one-to-one ratio nearest-neighbour matching for baseline demographic data and tricuspid valve-related parameters. Forty patients in each group were matched in this way. Parametric and nonparametric tests were performed for data analysis.Results: Statistically, postoperative mortality within 30 days was not significantly different between the two groups (P=1). No differences were found in serious adverse events, such as stroke or third-degree conduction block, between the two groups after 1:1 PSM (P=1 and P=0.480, respectively). The mean operation time for the MIMVS+TAP group was longer (232.13±36.05 min) than that for the MIMVS group (204.25±28.49 min; P<0.001). The same was true for the cardiopulmonary bypass (CPB) time (169.48±25.96 vs. 153.10±23.00 min; P=0.004) and aortic clamp time (110.80±17.37 vs. 101.00±14.38 min; P=0.005). The duration of the intensive care unit stay and the overall postoperative length of stay were not different between the two groups (P=0.734 and P=0.472, respectively). The postoperative systolic pulmonary artery pressure differed between the two groups [38.00±8.45 (MIMVS); 33.65±7.34 (MIMVS + TAP), P=0.022].Conclusions: Our study showed that totally endoscopic mitral valve surgery with concomitant TAP is just as safe and effective as isolated totally endoscopic mitral valve surgery, even with a long surgery duration. Our study also suggested that totally endoscopic mitral valve surgery with concomitant TAP can improve tricuspid function in patients.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted a cohort in Mitral valve disease requiring surgery (n=143). Concomitant tricuspid annuloplasty vs. Isolated minimally invasive mitral valve surgery was evaluated on Postoperative mortality within 30 days (p=1). Concomitant tricuspid annuloplasty during endoscopic mitral valve surgery had similar 30-day mortality (P=1) but lower postoperative systolic pulmonary artery pressure (33.65 vs 38.00; P=0.022).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: